The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Open accessAbstract
BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction. METHODS: We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects meta-analysis to estimate the effect of SGLT2 inhibitors on various clinical endpoints in heart failure The primary endpoint for this meta-analysis was time from randomisation to the occurrence of the composite of cardiovascular death or hospitalisation for heart failure. We assessed heterogeneity in treatment effects for the primary endpoint across subgroups of interest. This study is registered with PROSPERO, CRD42022327527. FINDINGS: Among 12 251 participants from DELIVER and EMPEROR-Preserved, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0·80 [95% CI 0·73-0·87]) with consistent reductions in both components: cardiovascular death (0·88 [0·77-1·00]) and first hospitalisation for heart failure (0·74 [0·67-0·83]). In the broader context of the five trials of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalisation for heart failure (0·77 [0·72-0·82]), cardiovascular death (0·87 [0·79-0·95]), first hospitalisation for heart failure (0·72 [0·67-0·78]), and all-cause mortality (0·92 [0·86-0·99]). These treatment effects for each of the studied endpoints were consistently observed in both the trials of heart failure with mildly reduced or preserved ejection fraction and across all five trials. Treatment effects on the primary endpoint were generally consistent across the 14 subgroups examined, including ejection fraction. INTERPRETATION: SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a large meta-analysis (308) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [308]
The cited source says what the claim attributes to it.
In the citing paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
The cited source says what the claim attributes to it.
In the citing paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [535]
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“A large recent meta-analysis (227) including data from EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) included 21,947 patients and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, fi r”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
In the citing paper
“The fi ndings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all fi ve trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationSolomon, S. D., Anavekar, N. S., Skali, H., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Wang, D., Pocock, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.561423 · Cited by 873
Self-citation
Research works printed but not linked: 1
- Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 · DOI · Paper page
Cited by
Sorted by citations
Items 701–800 of 1,000
Niu, S., Guan, D., Shi, L., Fonseca, V. A., Svensson, M., Ali, M. K., Sun, Y. V., Hu, X., Su, C., Yang, C., et al. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.015 · Cited by 1
Jamsheer, F., AlAhmed, A., Alshamlan, N. H., Abdali, N. M., Aljarmal, M., & Alsudairy, N. M. (2025) · Cureus · doi:10.7759/cureus.80610 · Cited by 1
Cost-effectiveness of dapagliflozin for the treatment of heart failure: a systematic review
Jiang, Z., Chen, D. X., Xiao, C., Fu, Y., & Zhang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572289 · Cited by 1
Heart Failure with Preserved Ejection Fraction in the Indian Context
Gupta, R., Choudhary, M., & Guptha, S. (2025) · Journal of Indian College of Cardiology · doi:10.4103/jicc.jicc_65_24 · Cited by 1
Vetrano, E., Galiero, R., Simeon, V., Palmiero, G., Cesaro, A., Caturano, A., Rinaldi, L., Salvatore, T., Ruggiero, R., Palo, M. R. D., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18081200 · Cited by 1
Implementation Approaches in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
Bhatt, A. S., Filippatos, G., & Vaduganathan, M. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.01.013 · Cited by 1
Self-citationGreene, S. J., Fonarow, G. C., & Butler, J. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2688 · Cited by 1
Patoulias, D., & Fragakis, N. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2784 · Cited by 1
Sawami, K., Tanaka, A., & Node, K. (2023) · Circulation · doi:10.1161/circulationaha.122.062333 · Cited by 1
Neuen, B. L., Jun, M., Wick, J., Kotwal, S. S., Badve, S. V., Jardine, M., Gallagher, M., Chalmers, J. P., Nallaiah, K., Perkovic, V., et al. (2023) · medRxiv · doi:10.1101/2023.06.26.23291881 · Cited by 1
Miname, M. H., & Santos, R. D. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad334 · Cited by 1
Natriuretic Peptides and Echocardiography: When We Use Tests to Guide Testing
Nolan, M. T., & Stanton, T. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.10.006 · Cited by 1
Chen, X., Yu, X., Lian, G., Tang, H., Yan, Y., Gao, G., Huang, B., Luo, L., & Xie, L. (2023) · Research Square · doi:10.21203/rs.3.rs-3784551/v1 · Cited by 1
Duan, Y., Wang, H., Li, G., Jing, H., & Li, W. (2024) · Research Square · doi:10.21203/rs.3.rs-4695907/v1 · Cited by 1
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF
Kamat, I., & Nair, A. P. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012432 · Cited by 1
Rezaee, M., Keykhaei, M., Koleini, N., Panesar, T., Li, S., Salvekar, N., Polhemus, D. J., Hu, C., Meddeb, M., Zhao, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.29.728910 · Cited by 1
Heart failure risk is accurately predicted by certain serum proteinsPreprint
Emilsson, V., Jonsson, B. G., Guðmundsdóttir, V., Axelsson, G. T., Frick, E. A., Jónmundsson, Þ., Steindorsdottir, A. E., Launer, L. J., Aspelund, T., Kortekaas, K. A., et al. (2022) · medRxiv · doi:10.1101/2022.10.11.22280881
Meta-analysis of DELIVER and EMPEROR-Preserved
Giles, R. (2022) · doi:10.55788/766d3286
Cleary, D., Hannou, S., Quiaios, L., Monney, P. A., Hullin, R., Wojtusciszyn, A., Büla, C., & Nguyen, S. (2022) · JMIG · doi:10.53738/revmed.2022.18.802.2057
Volpe, M., & Patrono, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac649
Guideline‐directed medical therapy improves not only left but also right heart function
Čerlinskaitė‐Bajorė, K., Mebazaa, A., & Čelutkienė, J. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2739
Schwinger, R. H. G., & Nitschmann, S. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01436-3
Selección de lo mejor del año 2022 en insuficiencia cardiaca
Mayoral, A. R., Santiago‐Vacas, E., Pérez, D. D., Bagudá, J. D. J., & González‐Costello, J. (2022) · REC CardioClinics · doi:10.1016/j.rccl.2022.10.009
HFpEF: Evidence from Recent Clinical Trials and New Perspectives
Saraiva, J. F. K., & de Moraes, N. D. R. (2022) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20220071
Selección de lo mejor del año 2022 en cardiología clínica y farmacoterapia cardiovascular
Gámez, J. M., Aguilera, A., Barrios, V., Escobar, C., Freixa‐Pamias, R., Marzoa‐Rivas, R., Rincon, L. M., & Vivas, D. (2023) · REC CardioClinics · doi:10.1016/j.rccl.2022.10.008
January 2023 at a Glance: Focus on Acute Heart Failure and Medical Therapy
Tomasoni, D., Adamo, M., & Metra, M. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2786
Cardiac assessment and management in older surgical patients
Amado, L. A., & Wijeysundera, D. N. (2023) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000393
MacDonald, B. J., Koshman, S. L., & Turgeon, R. D. (2023) · Canadian Family Physician · doi:10.46747/cfp.6903186
Patient decision aid for flozins in heart failure and ejection fraction greater than 40%
MacDonald, B. J., Koshman, S. L., & Turgeon, R. D. (2023) · Canadian Family Physician · doi:10.46747/cfp.6903181
Hyman, M. C., & Deo, R. (2023) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2022.12.005
New perspectives in the treatment of chronic heart failure
Nussbaumerová, B. (2023) · Vnitřní lékařství · doi:10.36290/vnl.2023.015
Metaanalyse: SGLT-2-Inhibitoren verbessern Prognose bei HFrEF und HFpEF
Franke, K. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1938-7042
Zieroth, S. R., & Rizi, S. S. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.022
Bancks, M. P. (2023) · Diabetes Care · doi:10.2337/dci23-0023
Lehrke, M. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01034-3
Fibroblast growth factor 23: novel determinants and associations with cardiorenal outcomes
de Jong, M. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.688240758 · Cited by 1
Die neuen Wunderdrogen - eine Einordnung aus kardiologischer Sicht
Schirmer, S. H. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4512-7
Addressing the Clinical and Economic Impact of Heart Failure
(2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89416
Cortés, M., Gonzalez, O. L., Lumpuy‐Castillo, J., Martínez-Albaladejo, S., Urquía, M. T., Lázaro, A. M. P., Becerra, J. A. B., Orejas, M., Lobato, M. Á. N., Palafox, E. M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3280284/v1
Application and Influence of Dapagliflozin in Patients with Type 2 Diabetes Mellitus
王, 永. (2023) · Medical Diagnosis · doi:10.12677/md.2023.133041
Zhou, G., de Vos, S., Schuiling‐Veninga, C. C. M., Bos, J., Rengerink, K. O., Pasmooij, A. M. G., Mol, P. G. M., de Bock, G. H., & Hak, E. (2023) · Clinical Epidemiology · doi:10.2147/clep.s418069
Management Heart Failure with Preserved Ejection Fraction: A Mini Review
Laksono, S., & Franata, R. (2023) · South East European Journal of Cardiology · doi:10.3889/seejca.2023.6051
Docherty, K. F. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.08.013
Self-citationIriowen, R., Edema, T. F., Dike, V., Ogundipe, T., Oluwatowoju, I., Nwatamole, B. C., Okonkwo, O. A., & Okobi, O. E. (2023) · American Journal of Health Medicine and Nursing Practice · doi:10.47672/ajhmn.1586
Az SGLT2-gátlók lehetséges hatásai a kardiovaszkuláris megbetegedésekben
Kosztin, A. (2023) · Cardiologia Hungarica · doi:10.26430/chungarica.2023.53.4.360 · Cited by 2
Depressed Proximal Glycolysis in Myocardium Of Human Heart Failure with Preserved Ejection FractionPreprint
Koleini, N., Meddeb, M., Keykhaei, M., Kwon, S., Zhao, L., Hahn, V. S., Sharma, K., Pearce, E. L., & Kass, D. A. (2023) · medRxiv · doi:10.1101/2023.09.30.23296261
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/na230038
Diallo, A., Carlos‐Bolumbu, M., & Galtier, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15320
Shubrook, J. H., Neumiller, J. J., Alicic, R. Z., Manley, T., & Tuttle, K. R. (2023) · Diabetology · doi:10.3390/diabetology4040039
Sodium–glucose cotransporter 2 inhibitors
Seferovic, P. M., Cosentino, F., Rosano, G., & Januzzi, J. L. (2023) · doi:10.1093/med/9780198891628.003.0050
Tratamiento actual de la insuficiencia cardíaca con fracción de eyección preservada
Quintero, M. A. R. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.icfracciondeeyeccion.art5
Insuficiencia cardíaca. Estrategias diagnósticas y terapéuticas
Amores, M., & Zamorano, J. L. (2023) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2023.12.004
Seoudy, H., Voran, J. C., & Frank, D. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3116
SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know
Greene, S. J., Fonarow, G. C., & Butler, J. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00624-2
Les complications macroangiopathiques chez les personnes âgées diabétiques
Duly‐Bouhanick, B., Bouillet, B., & Bauduceau, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(23)00299-7
Böhm, M., Perings, C., Bauersachs, J. K., Edelmann, F., Färber, G., Heidecker, B., Paul, M., & Pauschinger, M. (2024) · Die Kardiologie · doi:10.1007/s12181-023-00655-8
Highlights of the 2022 Brano Heart Failure Forum: Part One
Livil, U., Radovancevic, R., Vrtovec, B., & Gregorič, I. D. (2023) · The VAD Journal · doi:10.11589/vad/e2023914
Kindermann, M., & Ewen, S. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21003-7.00008-x
Are you giving men with heart failure the best care?
Hogan, G., Patel, H., & Patel, N. (2024) · Trends in Urology & Men s Health · doi:10.1002/tre.948
Huynh, Q. L., Burgess, J., Flentje, K., Tan, N., Batchelor, R., Marwick, T. H., & Shaw, J. E. (2024) · Diabetic Medicine · doi:10.1111/dme.15291
Aktuelle Therapie der Herzinsuffizienz mit mäßiggradig reduzierter und erhaltener Pumpfunktion
Störk, S., & Morbach, C. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2047-5013
Meybodi, S. M., Karimi, M. A., Mousazadeh, K., Pakmehr, S., Anar, M. A., Alizadeh, A., Poudineh, M., Zerangian, N., Rahmanian, M., Fathi, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3820980/v1
Komorbiditäten bei Herzerkrankungen – Ausmaß und Folgen
Cascorbi, I. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00679-8
Enhancing patient outcomes: 2023 focused clinical update on heart failure
Lehane, M., Docherty, A., Hyland, B., Simpson, M., & Macklin, L. (2024) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2023.0103
Systemerkrankung Herzinsuffizienz
Christa, M., & Maack, C. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00677-w
Schnittstellen in der kardiovaskulären Medizin
Maack, C. (2024) · Herz · doi:10.1007/s00059-024-05238-1
岳, 玺. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142635
李, 文. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143680
Update: Herzinsuffizienz mit erhaltener Pumpfunktion
Morbach, C., & Störk, S. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2096-7448
Dihoum, A., Brown, A. J. M., McCrimmon, R. J., Lang, C. C., & Mordi, I. R. (2024) · Research Square · doi:10.21203/rs.3.rs-4163334/v1
Sodium glucose transporters inhibitors in the management of heart failure
Singh, R. B., Chakravorty, S., Elmaraghi, O., Nabavizadeh, F., Elkilany, G. N., Jain, M., Shukla, A. K., Agarwal, A., Yaduvanshi, A., Mahajan, S., et al. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822972-9.00036-5
Use of Sodium-Glucose Co-transporter-2 Inhibitors after Acute Myocardial Infarction
Mikhail, N. E. (2024) · Journal of Diabetes and Clinical Research · doi:10.33696/diabetes.6.058
Stolz, L., & Hausleiter, J. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3277
Advances in Medical Therapies to Advance Patient Care
Dressler, D. D. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.04.009
Instrumental outcome modifiers to be considered among patients with acute heart failure
Hung, K.-C., & Chao, C. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132145
Marx, N., Müller‐Wieland, D., Espinola–Klein, C., Halle, M., Birkenhagen, A., Diemert, P., Mahfoud, F., Wienbergen, H., & Schütt, K. S. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00689-6
A Bibliometric Analysis of Comorbidity of Heart Failure and Type 2 Diabetes in 2015-2024Preprint
Liao, T., Wang, C., Tan, X., Xie, G., Liu, X., & Ouyang, F. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4822553
An update on the treatment of heart failure in people with diabetes: news from the ESC guidelines
Tuccinardi, F. (2024) · The Journal of AMD · doi:10.36171/jamd24.27.1.9
Clinical and instrumental diagnosis of heart failure
Pedretti, R. F. E. (2024) · The Journal of AMD · doi:10.36171/jamd24.27.1.7
Kardiomyopathie-Phänotypen – Unterschiede und Gemeinsamkeiten in der Behandlung
Bittner, D., & Raake, P. W. J. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2285-8006
Sweet relationship between SGLT2 inhibition and heart failure
Nabeshima, Y., Tanaka, A., & Node, K. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132223
Smetana, G. W., Romeo, G. R., Rosas, S. E., & Burns, R. B. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0764
Lyle, M. A., & Santos‐Gallego, C. G. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.05.009
Butts, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_3
Mikhail, N. (2023) · Clinical Research and Clinical Trials · doi:10.31579/2693-4779/114
Sodium-Glucose Cotransporter Inhibitors in Heart Failure
Sandhu, A. T., & Zheng, J. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.011
Tavares, S., Kanaganayagam, G. S., Lampridou, S., Phuyal, U., Singh, H., & Forsyth, F. (2024) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2024.0012
Flozins in Reducing Cardiovascular and Metabolic Risk: A Literature Review
Sieniawska, D., Sieniawska, J., & Proszowska, P. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52540
Simplifying Treatment of Congestion
Boorsma, E. M., Docherty, K. F., & Campbell, R. T. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.024
Self-citationPradhan, S., Kalanski, S., Tintut, Y., & Demer, L. L. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000942
Herzinsuffizienz bei Patienten mit Diabetes mellitus
Schütt, K. S., & Polzin, A. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2318-3573
Paradigm shift in diabetes care: Glucose-centric to cardio-metabolicrenal approach
Rameshkumar, T., & Katulanda, P. (2022) · Ceylon Journal of Medical Science · doi:10.4038/cjms.v59i1.5065
Diabetes and gout: another role for SGLT2 inhibitors?
Bailey, C. J. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241269178
宋, 琦. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482233
Targeting HFpEF: Unlocking the Potential of Glucagon Receptor Blockade
Padilla, L. S., & Schiattarella, G. G. (2024) · Circulation Research · doi:10.1161/circresaha.124.325130
McCallum, W. I., & Sarnak, M. J. (2024) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00042024
Larina, V. N., Kokorin, K. V. A., Иванович, Л. В., & Suvorova, N. A. (2024) · Russian Journal of Cardiology · doi:10.15829/15604071-2024-5915
Marques, F., Valicelli, F. H., Tanaka, D. M., & Simões, M. V. (2024) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240027 · Cited by 1
The Trajectory of Gliflozins: From Apple Tree Bark to Reduced Overall Mortality in Heart Failure
Marques, F., Valicelli, F. H., Tanaka, D. M., & Simões, M. V. (2024) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240027i
Metadata
- Authors
- Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D.
- Affiliations
- Brigham and Women's Hospital (US)
- British Heart Foundation (GB)
- Duke Medical Center (US)
- Yale University (US)
- University of Missouri–Kansas City (US)
- National University of Singapore (SG)
- Northwestern University (US)
- Corresponding author
- Solomon, Scott D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 400
- Issue
- 10354
- Pages
- 757-767
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4293353625
- Cited by
- 996
- References
- 24
- Citations by year
- 2026: 215 · 2025: 203 · 2024: 279 · 2023: 257 · 2022: 42
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-14)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, public-domain)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, public-domain)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company (NCT03057951)
- Pfizer
- AstraZeneca
- Sanofi
- National Institutes of Health
- Defense Acquisition Program Administration
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, DAPA-HF, EMPEROR-Preserved, EMPEROR-Reduced, cardiovascular risk stratification, treatment effect heterogeneity
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Stroke Volume, Randomized Controlled Trials as Topic, Ventricular Function, Left, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
